COVID-19 Positive Impact on Clinical Trials

Faye Woolf Talks to PharmaVoice about the Positive Impact of COVID-19 on the Clinical Trial Industry

FEBRUARY 2, 2021

Check-out PharmaVoice’s February edition of Commanders & Chiefs to see what Aperio’s Founder and CEO Faye Woolf had to say about getting back to the business of clinical trials and how COVID-19 forced the industry to adapt and adopt some much needed changes.

Read here.

About Aperio Clinical Outcomes

In a data driven industry, Aperio remains dedicated to transparency with clients and focused on the most important part of the process: people. Aperio provides full, customizable clinical research services across multiple therapeutic areas, as well as consulting services in Quality Assurance, Strategic Resourcing and Clinical Trial Technology. For more information: